INDEMNIFICATION AGREEMENTIndemnification Agreement • June 14th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • Delaware
This INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into effective as of [●], by and between Healthcare Royalty, Inc., a Delaware corporation (the “Company”), and [●], an individual (“Indemnitee”).
ROYALTY PURCHASE AGREEMENT dated as of January 6, 2018 between ANTIGENICS LLC, as Seller and HEALTHCARE ROYALTY PARTNERS III, L.P., AND CERTAIN AFFILIATED FUNDS IDENTIFIED HEREIN, collectively as PurchaserRoyalty Purchase Agreement • June 14th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • New York
ROYALTY PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of January 6, 2018, by and between ANTIGENICS LLC, a Delaware limited liability company (the “Seller”) and the entities set forth on Schedule 1 in the proportions set forth thereon (collectively, the “Purchaser”).
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. ROYALTY INTEREST ACQUISITION AGREEMENT Dated as of April 22, 2016 between Aviragen Therapeutics, Inc., Biota...Royalty Interest Acquisition Agreement • June 14th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • New York
This ROYALTY INTEREST ACQUISITION AGREEMENT is made and entered into as of April 22, 2016 by and between Aviragen Therapeutics, Inc. (formerly known as Biota Pharmaceuticals, Inc.), a Delaware corporation (“Aviragen”), Biota Holdings Pty Ltd (formerly known as Biota Holdings Limited), a corporation organized and existing under the laws of Victoria, Australia (“BHPL”), Biota Scientific Management Pty. Ltd., a corporation organized and existing under the laws of Victoria, Australia (“BSM”), and HealthCare Royalty Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (the “Agreement”).
PURCHASE AND SALE AGREEMENT DATED AS OF FEBRUARY 2, 2017 BETWEEN PORTOLA PHARMACEUTICALS, INC., AS SELLER, AND THE ENTITIES MANAGED BY HEALTHCARE ROYALTY MANAGEMENT, LLC IDENTIFIED HEREIN, COLLECTIVELY AS PURCHASERPurchase and Sale Agreement • June 14th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • New York
This PURCHASE AND SALE AGREEMENT (this “Agreement”) dated as of February 2, 2017 is between PORTOLA PHARMACEUTICALS, INC., a Delaware corporation (the “Seller”), and the entities managed by HealthCare Royalty Management, LLC set forth on Annex I (collectively, the “Purchaser”). Each of Seller and Purchaser are referred to in this Agreement as a “Party” and collectively as the “Parties”.
ASSET PURCHASE AGREEMENT between HARRIS FRC ACQUISITION, LP (as Purchaser) and HARRIS FRC CORPORATION (as Seller) Dated as of July 7, 2020Asset Purchase Agreement • June 14th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • New York
ASSET PURCHASE AGREEMENT, dated as of July 7, 2020, between Harris FRC Acquisition, LP, a Delaware limited partnership (“Purchaser”), and HARRIS FRC CORPORATION, a New Jersey corporation (“Harris FRC,” and, together with Purchaser, the “Parties”).
FORM OF LEGACY MANAGEMENT AGREEMENT1Management Agreement • June 14th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • Delaware
THIS MANAGEMENT AGREEMENT (the “Agreement”) is made as of [DATE] by and among [LEGACY HCR PARTNERSHIP]., a limited partnership organized under the laws of the State of Delaware (the “Partnership”), [LEGACY GENERAL PARTNER], a limited liability company organized under the laws of the State of Delaware (the “General Partner”), and HealthCare Royalty Management, LLC, a limited liability company organized under the laws of the State of Delaware (the “Management Company”).
